Accueil>>Signaling Pathways>> DNA Damage/DNA Repair>> CDK>>Ca2+ channel agonist 1

Ca2+ channel agonist 1

Catalog No.GC30977

L'agoniste 1 du canal Ca2+ est un agoniste du canal Ca2+ de type N et un inhibiteur de Cdk2, avec des EC50 de 14,23 μM et 3,34 μM, respectivement, et est utilisé comme traitement potentiel du dysfonctionnement du terminal nerveux moteur .

Products are for research use only. Not for human use. We do not sell to patients.

Ca2+ channel agonist 1 Chemical Structure

Cas No.: 1402821-24-2

Taille Prix Stock Qté
10mM (in 1mL DMSO)
354,00 $US
En stock
5mg
321,00 $US
En stock
10mg
459,00 $US
En stock
50mg
1 379,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

Ca2+ channel agonist 1 is an agonist of N-type Ca2+ channel and an inhibitor of Cdk2, with EC50s of 14.23 μM and 3.34 μM, respectively, and is used as a potential treatment for motor nerve terminal dysfunction.

Ca2+ channel agonist 1 (Compound 13d) is an agonist of N-type Ca2+ channel and an inhibitor of Cdk2, with EC50s of 14.23 μM and 3.34 μM, respectively. Ca2+ channel agonist 1 exhibits a ca. 2-fold increased agonism and a 22-fold decreased cdk2 kinase activity versus the standard, (R)-roscovitine[1].

[1]. Liang M, et al. Synthesis and biological evaluation of a selective N- and p/q-type calcium channel agonist. ACS Med Chem Lett. 2012 Oct 1;3(12):985-990.

Avis

Review for Ca2+ channel agonist 1

Average Rating: 5 ★★★★★ (Based on Reviews and 28 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Ca2+ channel agonist 1

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.